The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

被引：0
|
作者：
Wilson, J. M. [1 ]
Nikooienejad, A. [1 ]
Bowsman, L. M. [1 ]
Schroeder, J. M. [1 ]
Hamlin, D. M. [1 ]
Robins, D. A. [1 ]
Riesmeyer, J. S. [1 ]
Haupt, A. [1 ]
Duffin, K. L. [1 ]
Ruotolo, G. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1161
引用
收藏
页码：S558 / S559
页数：2
相关论文
共 50 条
  • [1] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    CIRCULATION, 2020, 142
  • [2] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [3] Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients
    Thomas, M. K.
    Nikooienejad, A.
    Bray, R.
    Cui, X.
    Wilson, J.
    Duffin, K.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S354 - S354
  • [4] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [5] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [6] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    DIABETES, 2019, 68
  • [7] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [8] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [9] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [10] TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES
    Pirro, V.
    Nikooienejad, A.
    Lin, Y.
    Willency, J.
    Wilson, J.
    Duffin, K.
    Robins, D.
    Milicevic, Z.
    Haupt, A.
    Thomas, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A165 - A165
12345